home / stock / nbix / nbix articles

NBIX Articles, Neurocrine Biosciences Inc.

Stock Information
Company Name: Neurocrine Biosciences Inc.
Stock Symbol: NBIX
Market: NASDAQ
Website: neurocrine.com
Menu
NBIX NBIX Quote NBIX Short NBIX News NBIX Articles NBIX Message Board
Get NBIX Alerts

News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder | Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform | Benzinga

H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...

CHARLES KEVIN GORMAN At Neurocrine Biosciences Decides to Exercises Options Worth $470K | Benzinga

A substantial insider activity was disclosed on February 14, as GORMAN, Chief Executive Officer at Neurocrine Biosciences (NASDAQ:NBIX), reported t...

Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise | Benzinga

Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. The st...
Why Is Neurocrine Biosciences Stock Trading Lower Today? | Benzinga

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in...

Why Is Neurocrine Biosciences Shares Trading Higher Today? | Benzinga

Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and ado...

GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday | Benzinga

Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. ...
What's Going On With Neurocrine Biosciences Stock Today? | Benzinga

Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in ad...

Next 10